AI Article Synopsis
- TB-SPRINT is a microbead-based assay designed for rapid detection of tuberculosis and multidrug-resistant TB, aiming to improve clinic and research laboratory outcomes.
- The study evaluated TB-SPRINT's performance against established systems, showing its accuracy in detecting rifampicin and isoniazid resistance ranged from 81% to 99%.
- Despite promising results, further enhancements are necessary for TB-SPRINT to meet In Vitro Diagnostics standards, with costs calculated at approximately USD 127.78 for mean cost and USD 109.94 for activity-based costing.
Article Abstract
Background: Molecular tests can allow the rapid detection of tuberculosis (TB) and multidrug-resistant TB (MDR-TB). TB-SPRINT 59-Plex Beamedex® is a microbead-based assay developed for the simultaneous spoligotyping and detection of MDR-TB. The accuracy and cost evaluation of new assays and technologies are of great importance for their routine use in clinics and in research laboratories. The aim of this study was to evaluate the performance of TB-SPRINT at three laboratory research centers in Brazil and calculate its mean cost (MC) and activity-based costing (ABC).
Methods: TB-SPRINT data were compared with the phenotypic and genotypic profiles obtained using Bactec™ MGIT™ 960 system and Genotype® MTBDRplus, respectively.
Results: Compared with MGIT, the accuracies of TB-SPRINT for the detection of rifampicin and isoniazid resistance ranged from 81 to 92% and 91.3 to 93.9%, respectively. Compared with MTBDRplus, the accuracies of TB-SPRINT for rifampicin and isoniazid were 99 and 94.2%, respectively. Moreover, the MC and ABC of TB-SPRINT were USD 127.78 and USD 109.94, respectively.
Conclusion: TB-SPRINT showed good results for isoniazid and rifampicin resistance detection, but still needs improvement to achieve In Vitro Diagnostics standards.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905027 | PMC |
| http://dx.doi.org/10.1186/s12879-019-4646-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multicenter evaluation of TB-SPRINT 59-Plex Beamedex®: accuracy and cost analysis.
BMC Infect Dis
December 2019
Centro de Pesquisa em Tuberculose, Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Article Synopsis
- TB-SPRINT is a microbead-based assay designed for rapid detection of tuberculosis and multidrug-resistant TB, aiming to improve clinic and research laboratory outcomes.
- The study evaluated TB-SPRINT's performance against established systems, showing its accuracy in detecting rifampicin and isoniazid resistance ranged from 81% to 99%.
- Despite promising results, further enhancements are necessary for TB-SPRINT to meet In Vitro Diagnostics standards, with costs calculated at approximately USD 127.78 for mean cost and USD 109.94 for activity-based costing.
Genomic characterization of MDR/XDR-TB in Kazakhstan by a combination of high-throughput methods predominantly shows the ongoing transmission of L2/Beijing 94-32 central Asian/Russian clusters.
BMC Infect Dis
June 2019
Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France.
Background: Kazakhstan remains a high-burden TB prevalence country with a concomitent high-burden of multi-drug resistant tuberculosis. For this reason, we performed an in depth genetic diversity and population structure characterization of Mycobacterium tuberculosis complex (MTC) genetic diversity in Kazakhstan with both patient and community benefit.
Methods: A convenience sample of 700 MTC DNA cultures extracts from 630 tuberculosis patients recruited from 12 out of 14 regions in Kazakhstan, between 2010 and 2015, was independently studied by high-throughput hybridization-based methods, TB-SPRINT (59-Plex, n = 700), TB-SNPID (50-Plex, n = 543).
TB-EFI, a novel 18-Plex microbead-based method for prediction of second-line drugs and ethambutol resistance in Mycobacterium tuberculosis complex.
J Microbiol Methods
September 2018
Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France. Electronic address:
Several diagnostic tests are being developed to detect drug resistance in tuberculosis. In line with previous developments detecting rifampicin and isoniazid resistance using microbead-based systems (spoligoriftyping and TB-SPRINT), we present here an assay called TB-EFI detecting mutations involved in resistance to ethambutol, fluoroquinolones and the three classical injectable drugs (kanamycin, amikacin and capreomycin) in Mycobacterium tuberculosis. The proposed test includes both wild-type and mutant probes for each targeted locus.
View Article and Find Full Text PDFRetraction: Spoligotyping analysis of Mycobacterium tuberculosis with TB-sprint technology.
J Biol Regul Homeost Agents
January 2018
Mycobacterium tuberculosis complex genotypes circulating in Nigeria based on spoligotyping obtained from Ziehl-Neelsen stained slides extracted DNA.
PLoS Negl Trop Dis
February 2018
Institut for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris Sud, Université Paris-Saclay, Gif-sur-Yvette, France.
Article Synopsis
- All State TB control programs in Nigeria submitted smears for analysis, resulting in DNA extraction from 929 slides for drug-resistance and spoligotyping analysis.
- The study found that 59.1% of samples yielded spoligotyping results, revealing that half belonged to the L4 Cameroon sublineage with geographic variations across the country.
- This research provides crucial insight into the genetic epidemiology of M. tuberculosis in Nigeria, using rapid spoligotyping from stained slides to enhance understanding of TB patterns.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!